

## QUESTIONNAIRE FOR ORGANIC IMPURITIES ASSESSMENT

Karlstraße 2  
79650 Schopfheim (bei Basel)  
Telefon +49 7622 6 66 86 – 70 Fax – 77  
service@gmp-verlag.de  
www.gmp-verlag.de

Vorstand:  
Barbara Peither, Thomas Peither

In order to perform a toxicological evaluation and risk assessment of the organic impurity under review, its chemical structure should be provided. Furthermore, information on the product administration route, the maximum daily intake and the treatment duration should also be provided by the client.

Please note that this information is necessary for performing an accurate and reliable toxicological evaluation and risk assessment. The purpose of this questionnaire is to compile and interpret the results on both the impurity and the drug product. In this way, the conclusions extracted in the subsequent risk analysis will be reliable for regulatory purposes.

REGULATORY REQUIREMENTS	
Is the toxicological evaluation of the organic impurity required as part of a registration dossier?	YES <input type="checkbox"/> NO <input type="checkbox"/>
Is it necessary to set a specification for the organic impurity in the finished product?	YES <input type="checkbox"/> NO <input type="checkbox"/>
Does the impurity appear as an out of tendency or out of specification result?	YES <input type="checkbox"/> NO <input type="checkbox"/>
Does a deficiency letter of a governmental agency exist in relation to the organic impurity, and if so, what are the requirements?	
IMPURITY DESCRIPTION	
Impurity described in Pharmacopoeia (Ph. Eur, USP)	YES <input type="checkbox"/> NO <input type="checkbox"/>
Impurity description: Chemical name, CAS registry number, SMILES notation, molecular weight and molecular formula... (please specify if known)	
Are there any internal preclinical tests performed? (either with the product containing the impurity or the isolated impurity, please specify if available)	
PRODUCT DESCRIPTION	
Administration route of the pharmaceutical product	
Maximum daily dose of the pharmaceutical product	
Average treatment duration (Lifelong treatment, chronic exposure, short-term exposure, single administration)	



*Maas & Peither*  
GMP VERLAG

MAAS & PEITHER AG

---

**Your contact details:**

\_\_\_\_\_  
company name for the report

\_\_\_\_\_  
company address for the report

\_\_\_\_\_  
customer name

\_\_\_\_\_ email

\_\_\_\_\_ phone number

\_\_\_\_\_  
billing address of the company (if different)

\_\_\_\_\_  
comments

**Please return to:**

email: [cynthia.schulz@gmp-verlag.de](mailto:cynthia.schulz@gmp-verlag.de) or fax: +49 7622 66686-77

Please note our privacy policy: [www.gmp-publishing.com/en/privacy-statement](http://www.gmp-publishing.com/en/privacy-statement)